I would love to hear that… that our efficacy and
Post# of 148050
(Total Views: 653)
Posted On: 05/12/2022 2:16:35 AM
I would love to hear that… that our efficacy and safety are above all others for NAFLD/NASH. That a new big Pharma partner has taken the reigns and will finish the phase 3 trial by ourself with just Leronlimab or even with another complimentary drug to progress the results. I am not sure the FDA would allow a phase 3 with an additional drug added at this point in trials and might reset the progress to regress to a phase two for safety only… to be proven first.
That’s the concern going forward. Adding another drug could take away our so far unblemished safety record that we think we have. Soon we will know if that’s true with the aggregated assessed safety look at our overall 20 trials to date. It will be interesting to see what we have been told all along that there has never been a safety issue of any kind with Leronlimab. This is what we hope to be proven true and recognition by those in power to reinstate our trials and progress our move out of the proverbial dog house into safety territory with only great results in NAFLD/NASH and mTNBC and HIV. Having the non-toxic label and safer than placebo will suit us very good going forward in all trials. As one former promoter once said… “safer than saline water.” This would be a great assessment. We can only hope it works this way.
Am I the only one sitting on pins and needles waiting for the news to break at the June 25th Nash conference? Hoping for nothing but great days once the release of information we all know should be better that the 350mg open trial. Watching the climb upward of the stock price like it once did.
It’s tougher every day waiting for me. At least… I am not getting up in the middle of the night looking for news at 3am like I use to.. being on the west coast. It was nice to know that in order to be in the conference you could not announce your trial results prior to the conference. That is allowing me some good sleep lately. Knowing when the news should be revealed is everything.
I still can’t wait… damn it!
That’s the concern going forward. Adding another drug could take away our so far unblemished safety record that we think we have. Soon we will know if that’s true with the aggregated assessed safety look at our overall 20 trials to date. It will be interesting to see what we have been told all along that there has never been a safety issue of any kind with Leronlimab. This is what we hope to be proven true and recognition by those in power to reinstate our trials and progress our move out of the proverbial dog house into safety territory with only great results in NAFLD/NASH and mTNBC and HIV. Having the non-toxic label and safer than placebo will suit us very good going forward in all trials. As one former promoter once said… “safer than saline water.” This would be a great assessment. We can only hope it works this way.
Am I the only one sitting on pins and needles waiting for the news to break at the June 25th Nash conference? Hoping for nothing but great days once the release of information we all know should be better that the 350mg open trial. Watching the climb upward of the stock price like it once did.
It’s tougher every day waiting for me. At least… I am not getting up in the middle of the night looking for news at 3am like I use to.. being on the west coast. It was nice to know that in order to be in the conference you could not announce your trial results prior to the conference. That is allowing me some good sleep lately. Knowing when the news should be revealed is everything.
I still can’t wait… damn it!
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼